Animal Models of Cardiovascular Disease;Modelos animales de enfermedad cardiovascular

Revista Espanola de Cardiologia

Volumn 62, Issue 1, 2009, Pages 69-84

  Chorro, Francisco J ^a   Such Belenguer, Luis ^a   López Merino, Vicente ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Animal models; Cardiovascular research; Preclinical research

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATE; APOLIPOPROTEIN A; COMPLEMENTARY DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; DISEASE MODEL; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; GENE MUTATION; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; IMAGING SYSTEM; ISOLATED HEART; MEDICAL RESEARCH; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMALL MAMMAL; SPECIES COMPARISON;

ANIMALS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; TISSUE CULTURE TECHNIQUES;

EID: 59749091024     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)70023-5     Document Type: Article

References (111)

1. Hearse D.J., and Sutherland F.J. Experimental models for the study of cardiovascular function and disease. Pharmacol Res 41 (2000) 597-603
2. Hamlin R.L. Animal models of ventricular arrhythmias. Pharmacol Ther 113 (2007) 276-295
3. Roths J.B., Foxworth W.B., McArthur M.J., Montgomery C.A., and Kier A.B. Spontaneous and engineered mutant mice as models for experimental and comparative pathology: history, comparison, and developmental technology. Lab Anim Sci 49 (1999) 12-34
4. Yong S.L., and Wang Q.K. Animal models for cardiac arrhythmias. Methods Mol Med 129 (2006) 127-148
5. Tamargo J., Caballero R., Núñez L., Gómez R., Vaquero M., and Delpón E. Genetically engineered mice as a model for studying cardiaca arrhythmias. Front Biosci 12 (2007) 22-38
6. Nattel S., Shiroshita-Takeshita A., Brundel B.J., and Rivard L. Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis 48 (2005) 9-28
7. Dalloz F., Osinska H., and Robbins J. Modelos animales genéticamente modificados en investigación cardiovascular. Rev Esp Cardiol 54 (2001) 764-789
8. Kantor B., Ashai K., Holmes Jr. D.R., and Schwartz R.J. The experimental animal models for assessing treatment of reestenosis. Cardiovasc Radiat Med 1 (1999) 48-54
9. Technical Expert Working Group for the revision of directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes. Final report sub-group on ethical review. Bruselas: Comisión Europea; 2003.
10. NIH Guide for the care and use of laboratory animals. ILAR, National Research Council, 1966.
11. Zadelaar S., Kleemann R., Verschuren L., De Vries-Van der Weij J., Van der Hoorn J., Princen H.M., et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27 (2007) 1706-1721
12. Terrar D.A., Wilson C.M., Graham S.G., Bryant S.M., and Heath B.M. Comparison of guinea-pig ventricular myocites and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization. J Pharmacol Toxicol Methods 56 (2007) 171-185
13. Caballero R., Delpón E., Valenzuela C., Longobardo M., and Tamargo J. Losartan and its metabolite E3174 modify cardiac deleyed rectifier K(+) currents. Circulation 101 (2000) 1199-1205
14. Caballero R., Moreno I., Gonzalez T., Arias C., Valenzuela C., Delpon E., et al. Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go related gene channels. Circulation 107 (2003) 889-895
15. Tutor A.S., Delpón E., Caballero R., Gómez R., Núñez L., Vaquero M., et al. Association of 14-3-3 proteins to B1-adrenergic receptors modulates Kv11.1K+ channel activity in recombinant systems. Mol Biol Cell 17 (2006) 4666-4674
16. Weerapura M., Nattel S., Courtemanche M., Doem D., Ethier N., and Ebert T. State-dependent barium block of wild-type and inactivation-deficient HERG channels in Xenopus oocytes. J Physiol 526 (2000) 265-278
17. Beaumont J., Arias T., Ravassa S., and Diez J. Overexpression of human truncated peroxisome proliferator-activated receptor (alpha) induces apoptosis in HL-1 cardiomyocytes. Cardiovasc Res 79 (2008) 458-460
18. Yuasa S., and Fukuda K. Recent advances in cardiovascular regenerative medicine: the induced pluripotent stem cell era. Expert Rev Cardiovasc Ther 6 (2008) 803-810
19. 2+-frequency relationships: similarities to dog and human. Cardiovasc Res 61 (2004) 77-86
20. Endoh M. Force-frequency relationship in intact mammalian ventricularmyocardium: physiological and pathophysiological relevance. Eur J Pharmacol 500 (2004) 73-86
21. + current in guinea pig ventricular myocytes: voltage-independent and timedependent block of the slowly activating component. Circ Res 76 (1995) 223-235
22. Perez O., Valenzuela C., Delpón E., and Tamargo J. Electrophysiological effects of CI-980, a tubulin binding agent, on guinea pig papillary muscles. Br J Pharmacol 120 (1997) 187-192
23. Janse M.J., Van Capelle F.J., Anderson R.H., Billette J., Becker A.E., and Durrer D. Correlation between electrophysiologic recordings and morphologic findings in the rabbit atrioventricular node. Arch Int Physiol Biochim 82 (1974) 331-332
24. Van Capelle F.J., Janse M.J., Varghese P.J., Freud G.E., Mater C., and Durrer D. Spread of excitation in the atrioventricular node of isolated rabbit hearts studied by multiple microelectrode recordings. Circ Res 31 (1972) 602-616
25. Cavero I., Mestre M., Guillon J.M., Hevillet E., and Roach A.G. Preclinical in vitro cardiac electrophysiology. A method of predicting arrhythmogenic potential of antihistamines in humans. Drug Safety 21 Suppl 1 (1999) 19-31
26. Hagashi S., Kii Y., Tabo M., Fukuda H., Itoh T., Shimosato T., et al. QT Prodact: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. J Pharmacol Sci 99 (2005) 423-437
27. Sugiyama A., Motomura S., and Hashimoto K. Comparison of cardiovascular effects of a novel class IC atiarrhythmic agent, NIK-244, with those of flecainide in isolated canine heart preparations cross-circulated with a donor dog. Jpn J Pharmaco 56 (1991) 1-12
28. Galinanes M., and Hearse D.J. Assessment of ischemic injury and protective interventions: the Langendorff versus the working rat heart preparation. Can J Cardiol 6 (1990) 83-91
29. Brugada J., Boersma L., Abdollah H., and Kirchhof C. Echowave termination of ventricular tachycardia. A common mechanism of termination of reentrant arrhythmias by various pharmacological interventions. Circulation 85 (1992) 1879-1887
30. Boersma L., Zetelaki Z., Brugada J., and Allessie M. Polymorphic reentrant ventricular tachycardia in the isolated rabbit heart studied by high-density mapping. Circulation 105 (2002) 3053-3061
31. Chorro F.J., Cánoves J., Guerrero J., Mainar L., Sanchis J., Such L., et al. Alteration of ventricular fibrillation by flecainide, verapamil, and sotalol: an experimental study. Circulation 101 (2000) 1606-1615
32. Chorro F.J., Trapero I., Guerrero J., Such L.M., Canoves J., Mainar L., et al. Modification of ventricular fibrillation activation patterns induced by local stretching. J Cardiovasc Electrophysiol 16 (2005) 1087-1096
33. Trapero I., Chorro F.J., Such-Miquel L., Cánoves J., Tormos A., Pelechano F., et al. Efectos de la estreptomicina en las modificaciones de la activación miocárdica durante la fibrilación ventricular inducidas por el estiramiento. Rev Esp Cardiol 61 (2008) 201-205
34. Franz M.R. Current status of monophasic action potential recording: theories, measurements and interpretations. Cardiovasc Res 41 (1999) 25-40
35. Gray R.A., Pertsov A.M., and Jalife J. Spatial and temporal organization during cardiac fibrillation. Nature 392 (1998) 75-78
36. Moreno J., Zaitsev A.V., Warren M., Berenfeld O., Kalifa J., Lucca E., et al. Effect of remodelling, stretch and ischemia on ventricular fibrillation frequency and dynamics in a heart failure model. Cardiovasc Res 65 (2005) 158-166
37. Valderrábano M., Yang J., Omichi C., Kil J., Lamp S.T., Qu Z., et al. Frequency analysis of ventricular fibrillation in swine ventricles. Circ Res 90 (2002) 213-222
38. Salama G., and London B. Mouse models of Long QT syndrome. J Physiol 578 (2007) 43-53
39. Nilles K.M., and London B. Knockin animal models of inherited arrhythmogenic diseases: what have we learned from them. J Cardiovasc Electrophysiol 18 (2007) 1117-1125
40. Williams K.J., Feig J.E., and Fisher E.A. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med 5 (2008) 91-102
41. Wouters K., Shiri-Sverdlov R., Van Gorp P.J., Van Bilsen M., and Hofker M.H. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoE and LDLr mice. Clin Chem Lab Med 43 (2005) 470-479
42. Lebeche D., Dalal R., Jang M., Del Monte F., and Hajjar R.J. Transgenic models of heart failure: Elucidation of the molecular mechanisms of heart disease. Heart Fail Clin 1 (2005) 219-236
43. Dillmann W.H. Calcium regulatory proteins and their alteration by transgenic approaches. Am J Cardiol 83 (1999) H89-H91
44. Babu G.J., and Periasamy M. Transgenic mouse models for cardiac dysfunction by a specific gene manipulation. Methods Mol Med 112 (2005) 365-377
45. Schulz R., and Heusch G. Connexin 43 and ischemic preconditioning. Cardiovasc Res 62 (2004) 335-344
46. Ferdinandy P., Schulz R., and Baxter G.F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59 (2007) 418-458
47. Golino P., Maroko P.R., and Carew T.E. The effect of acute hypercholesterolemia on myocardial infarct size and the non-reflow phenomenon during coronary occlusion-reperfusion. Circulation 75 (1987) 292-298
48. Friedman M., Byers S.O., and Rosenman R.H. Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion. Proc Soc Exp Biol Med 95 (1957) 586-588
49. Wissler R.W., and Vesselinovitch D. Studies of regression of advanced atherosclerosis in experimental animals and man. Ann N Y Acad Sci 275 (1976) 363-378
50. Miyazaki A., Sakuma S., Morikawa W., Takiue T., Miake F., Terano T., et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterolfed rabbits. Arterioscler Thromb Vasc Biol 15 (1995) 1882-1888
51. Aikawa M., and Libby P. Lipid lowering reduces proteolytic and prothrombotic potential in rabbit atheroma. Ann N Y Acad Sci 902 (2000) 140-152
52. Williams K.J., Werth V.P., and Wolff J.A. Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle. Perspect Biol Med 27 (1984) 417-431
53. Maruffo C.A., and Portman O.W. Nutritional control of coronary artery atherosclerosis in the squirrel monkey. J Atheroscler Res 8 (1968) 237-247
54. Armstrong M.L., and Megan M.B. Evidence of regression of atherosclerosis in primates and man. Postgrad Med J 52 (1976) 456-461
55. Armstrong M.L., Warner E.D., and Connor W.E. Regression of coronary atheromatosis in rhesus monkeys. Circ Res 27 (1970) 59-67
56. Daoud A.S. Sequential morphologic studies of regression of advanced atherosclerosis. Arch Pathol Lab Med 105 (1981) 233-239
57. Walsh A., Ito Y., and Breslow J.L. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. J Biol Chem 264 (1989) 6488-6494
58. Plump A.S., Smith J.D., Hayek T., Aalto-Setälä K., Walsh A., Verstuyft J.G., et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71 (1992) 343-353
59. Tangirala R.K., Tsukamoto K., Chun S.H., Usher D., Puré E., and Rader D.J. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100 (1999) 1816-1822
60. Tsukamoto K., Smith P., Glick J.M., and Rader D.J. Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. J Clin Invest 100 (1997) 107-114
61. Harris J.D., Graham I.R., Schepelman S., Stannard A.K., Roberts M.L., Hodges B.L., et al. Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) decidient mice by administration of a second generation [E1(-), E3(-), polymerase (-) adenovirus vector expressing human apoE. Hum Mol Genet 11 (2002) 43-58
62. Trogan E., Feig J.E., Dogan S., Rothblat G.H., Angeli V., Tacke F., et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A 103 (2006) 3781-3786
63. Trogan E., Fayad Z.A., Itskovich V.V., Aguinaldo J.G., Mani V., Fallon J.T., et al. Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia. Arterioscler Thromb Vasc Biol 24 (2004) 1714-1719
64. Casani L., Segales E., Vilahur G., Bayés de Luna A., and Badimón L. Moderate daily intake of red wine inhibits mural thrombosis and monocyte tissue factor expression in an experimental porcine model. Circulation 110 (2004) 460-465
65. Badimón L., Turitto V., Rosemark J.A., Badimón J.J., and Fuster V. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetics materials: deposition of indium 111-labeled platelets on collagen, subendothelium and expanded polytetrafluorethylene. J Lab Clin Med 110 (1987) 706-718
66. Braunwald E., and Maroko P.R. Protection of the ischemic myocardium. Cardiovasc Dis 2 (1975) 129-147
67. Maroko P.R., Kjekshus J.K., Sobel B.E., Watanabe T., Covell J.W., Ross J., et al. Factors influencing infarct size following experimental coronary artery occlusion. Circulation 43 (1971) 67-82
68. Schaper J. Ultrastructure of the myocardium in acute ischemia. In: Schaper W. (Ed). The pathophysiology of myocardial perfusion (1979), Elsevier, Amsterdam 581-674
69. Schaper J. Ultrastructural changes of the myocardium in regional ischemia and infarction. Eur Heart J 7 Suppl B (1986) 3-9
70. Schaper J., and Schaper W. Time course of myocardial necrosis. Cardiovasc Drugs Ther 2 (1988) 17-25
71. Jennings R.B., Baum J., and Herdson P. Fine structural changes in myocardial ischemic injury. Arch Pathol 79 (1965) 135-143
72. Jennings R.B., and Ganote E. Structural changes in myocardium during acute ischemia. Circ Res 35 Suppl 3 (1974) 156-172
73. Jennings R.B., Reimer K.A., Hill M.L., and Mayer S.E. Total ischemia in dog hearts, in vitro. 1. Comparison of high energy phosphate production, utilization, and depletion, and of adenine nucleotide catabolism in total ischemia in vitro vs severe ischemia in vivo. Circ Res 49 (1981) 892-900
74. Huang Y., Rabb H., and Womer K.L. Ischemia-reperfusion and immediate T cell responses. Cell Immunol 248 (2007) 4-11
75. Kroemer G., Galluzzi L., and Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 87 (2007) 99-163
76. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
77. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol 285 (2003) H579-H588
78. Yellon D.M., and Downey J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83 (2003) 1113-1151
79. Armstrong S.C. Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res 61 (2004) 427-436
80. Hausenloy D.J., and Yellon D.M. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70 (2006) 240-253
81. Jones S.P., and Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40 (2006) 16-23
82. Otani H. Reactive oxygen species as mediators of signal transduction in ischemic preconditioning. Antioxid Redox Signal 6 (2004) 449-469
83. Rodriguez-Sinovas A., Boengler K., Cabestrero A., Gres P., Morente M., Ruiz-Meana M., et al. Translocation of connexin 43 in the inner mithocondrial membrane of cardiomyocytes through the heat shock protein 90-dependent TOM pathway and its importance in cardioprotection. Circ Res 99 (2006) 93-101
84. Garcia-Dorado D., Vinten-Johansen J., and Piper H.M. Bringing preconditioning and postconditioning into focus. Cardiovasc Res 70 (2006) 167-169
85. Recchia F.A., and Lionetti V. Animal models of dilated cardiomyopathy for translational research. Vet Res Commun 31 Suppl 1 (2007) 35-41
86. Christensen G., Wang Y., and Chien K.R. Physiological assessment of complex cardiac phenotypes in genetically engineered mice. Am J Physiol 272 (1997) H2513-H2524
87. Whipple G.H., Sheffield L.T., Woodman E.G., Theophilis C., and Friedman S. Reversible congestive heart failure due to chronic rapid stimulation of the normal heart. Proc N Engl Cardiovasc Soc 20 (1962) 39-40
88. Carmeliet E. Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Physiol Rev 79 (1999) 917-1017
89. Janse M.J., and Wit A.L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 69 (1989) 1049-1169
90. Harris A.S., and Guevara Rojas A. The initiation of ventricular fibrillation due to coronary occlusion. Exp Med Surg 1 (1943) 105-111
91. Harris A.S. Delayed development of ventricular ectopic rhythms following experimental coronary occlusion. Circulation 1 (1950) 1318-1328
92. Taggart P., and Yellon D.M. Preconditioning and arrhythmias. Circulation 106 (2002) 2999-3001
93. Schwartz P.J., Billman G.E., and Stone H.L. Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with healed myocardial infarction: an experimental preparation for sudden cardiac death. Circulation 69 (1984) 790-800
94. Schwartz P.J., La Rovere M.T., and Vanoli E. Autonomic nervous system and sudden death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 85 Suppl 1 (1992) 77-91
95. Wit A.L., and Rosen M.R. After depolarizations and triggered activity. In: Fozzard H.A., Haber E., Jennings R.B., Katz A.M., and Morgan H.E. (Eds). The heart and cardiovascular system (1986), Raven Press, New York 1449-1490
96. Wijffels M.C., Kirchhof C.J., Dorland R., and Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92 (1995) 1954-1968
97. Wijffels M.C., Kirchhof C.J., Dorland R., Power J., and Allessie M.A. Electrical remodelling due to atrial fibrillation in chronically instrumented conscious goats: Roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 96 (1997) 3710-3720
98. Morillo C.A., Klein G.J., Jones D.L., and Guiraudon C.M. Chronic rapid atrial pacing. Structural, functional and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 91 (1995) 1588-1595
99. Allessie M.A., Boyden P.A., Camm A.J., Kleber A.G., Lab M.J., and Legato M.J. Pathophysiology and prevention of atrial fibrillation. Circulation 103 (2001) 769-777
100. Harada A., D'Agostino Jr. H.J., Schuessler R.B., Boineau J.P., and Cox J.L. Right atrial isolation: a new surgical treatment for supraventricular tachycardia. I. Surgical technique and electrophysiologic effects. J Thorac Cardiovasc Surg 95 (1988) 643-650
101. Cox J.L., Schuessler R.B., D'Agostino Jr. H.J., Stone C.M., Chang B.C., Cain M.E., et al. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 101 (1991) 569-583
102. Huang S.K., Bharati S., Graham A.R., Gorman G., and Lev M. Chronic incomplete atrioventricular block induced by radiofrequency catheter ablation. Circulation 80 (1989) 951-961
103. Chorro F.J., Sanchis J., Lopez-Merino V., Such L., Cerdá M., and Burguera M. Transcatheter ablation of the sinus node in dogs using high-frequency current. Eur Heart J 11 (1990) 82-89
104. Chorro F.J., Mainar L., Canoves J., Sanchis J., Such L.M., Porres J.C., et al. Características de los electrogramas auriculares registrados en las líneas de bloqueo producidas con radiofrecuencia en un modelo experimental. Rev Esp Cardiol 53 (2000) 1596-1606
105. Chorro F.J., Blasco E., Trapero I., Cánoves J., Ferrero A., Mainar L., et al. Selective myocardial isolation and ventricular fibrillation. Pacing Clin Electrophysiol 30 (2007) 359-370
106. Chorro F.J., Guerrero J., Cánoves J., Trapero I., Mainar L., Pelechano F., et al. Modificaciones de las características espectrales de la fibrilación ventricular en las lesiones producidas con radiofrecuencia. Estudio experimental. Rev Esp Cardiol 61 (2008) 394-403
107. Wijffels M.C., Dorland R., Mast F., and Allessie M.A. Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: Effects of cibenzoline, hydroquinidine, flecainide, and D-sotalol. Circulation 101 (2000) 260-267
108. Mirowsky M., Mower M.M., Langer A., Heilman M.S., and Schreibman J. A chronically implanted system for automatic defibrillation in active conscious dogs. Experimental model for treatment of sudden death from ventricular fibrillation. Circulation 58 (1978) 90-94
109. James J.F., Hewett T.E., and Robbins J. Cardiac physiology in transgenic mice. Circ Res 82 (1998) 407-415
110. Epstein F.H. MR in mouse models of cardiac disease. NMR Biomed 20 (2007) 238-255
111. Stett A., Egert U., Guenther E., Hofmann F., Meyer T., Nisch W., et al. Biological application of microelectrode arrays in drug discovery and basic research. Anal Bioanal Chem 377 (2003) 486-495